|
|
 Previous Article | Table of Contents | Next Article 
Effects of recombinant human interleukin-3 in aplastic anemia
A Ganser, A Lindemann, G Seipelt, OG Ottmann, M Eder, S Falk, F Herrmann, JP Kaltwasser, P Meusers and M Klausmann
Department of Hematology, University of Frankfurt, West Germany.
In a phase I/II study, nine patients with aplastic anemia were treated with
recombinant human interleukin-3 (rhIL-3) to assess the toxicity and
biologic effects of this multipotential hematopoietic growth factor. Doses
ranging from 250 micrograms/m2 to 500 micrograms/m2 were administered as
subcutaneous bolus injections daily for 15 days. An increase in platelet
counts from 1,000/microL to 31,000/microL was induced by rhIL-3 in one
patient, and an increase in reticulocyte counts by more than 10,000/microL
in four patients. The blood leukocyte counts temporarily increased in eight
patients 1.5- to 3.3-fold (median, 1.8-fold), mainly due to an increase in
the number of neutrophils, eosinophils, lymphocytes, and monocytes. In two
patients, bone marrow cellularity increased from 7% to 33% and from 10% to
80%, respectively, but without resulting in a substantial improvement of
peripheral blood counts. Mild side effects (headache and flushing) were
observed in some patients, while low-grade fever occurred in all patients.
Transient thrombocytopenia necessitating discontinuation of rhIL-3
treatment occurred in one patient. In conclusion, rhIL-3 can stimulate
hematopoiesis in patients with aplastic anemia; however, no lasting effects
were obtained.
Volume 76,
Issue 7,
pp. 1287-1292,
10/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Kurzrock
Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited
Clin. Cancer Res.,
February 15, 2005;
11(4):
1361 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.G. Begley, R. Basser, R. Mansfield, B. Thomson, W.R.L. Parker, J. Layton, B. To, J. Cebon, W.P. Sheridan, R.M. Fox, et al.
Enhanced Levels and Enhanced Clonogenic Capacity of Blood Progenitor Cells Following Administration of Stem Cell Factor Plus Granulocyte Colony-Stimulating Factor to Humans
Blood,
November 1, 1997;
90(9):
3378 - 3389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eder, G. Geissler, and A. Ganser
IL-3 in the Clinic
Stem Cells,
September 1, 1997;
15(5):
327 - 333.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K Usuki, T Tahara, S Iki, M Endo, M Osawa, K Kitazume, T Kato, H Miyazaki, and A Urabe
Serum thrombopoietin level in various hematological diseases
Stem Cells,
September 1, 1996;
14(5):
558 - 565.
[Abstract]
|
|
|
|
|
